Formula III Compounds Targeting eIF5B for Nematode Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anthelmintic drugs face challenges due to emerging resistance in nematodes, limited treatment options for parasitic nematode infections, and environmental concerns, necessitating the development of new compounds effective against a wide range of nematode species.
Innovation Solution
Compounds of Formula (III) are developed, which exhibit inhibitory activity against various nematode species, including Cooperia oncophora and Haemonchus contortus, by targeting specific molecular mechanisms to incapacitate parasitic nematodes without inducing genetic resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anthelmintic drugs are used to treat nematode infections, then treatment efficacy is achieved against current nematode strains, but resistance develops in nematodes reducing future effectiveness
Solution Approach 1:
The patent applies a completely novel mechanism of action that inverts the traditional approach by targeting protein synthesis initiation (eIF5B) rather than disrupting nervous system function. This inversion of the therapeutic target prevents resistance development because nematodes have not been exposed to this mechanism, thereby maintaining long-term treatment efficacy.
Solution Approach 2:
The patent changes the fundamental parameter of mechanism of action from neurotoxicity to protein synthesis inhibition. By targeting eIF5B and disrupting the GTP-dependent conformational change required for ribosome function, the compound operates through a entirely different biochemical pathway, preventing cross-resistance with existing anthelmintics.
2Reliability
If chemical nematicides are used to control plant parasitic nematodes, then crop protection is achieved, but environmental toxicity and human safety concerns arise
Solution Approach 1:
The patent converts the previously harmful approach of neurotoxic disruption into a beneficial selective mechanism that targets essential protein synthesis machinery. The eIF5B inhibitor selectively disrupts nematode protein synthesis while sparing mammalian systems due to differences in eIF5B structure and function, thereby eliminating environmental toxicity concerns while maintaining crop protection.
Solution Approach 2:
The compound acts as a selective intermediary that exploits biochemical differences between nematode and mammalian eIF5B. The molecule binds to the nematode eIF5B protein and disrupts its function, while the structural differences in mammalian eIF5B prevent binding, creating a safe intermediary treatment that protects crops without harming the environment or human health.
3Adaptability or versatility
If limited treatment options are used for parasitic nematode infections, then current infections can be managed, but broader spectrum activity is needed to address emerging resistance
Solution Approach 1:
The patent achieves universality by targeting a fundamental and highly conserved protein synthesis mechanism (eIF5B) that is essential across all nematode species. This single mechanism of action provides broad-spectrum activity against diverse nematodes including hookworms, roundworms, whipworms, and plant-parasitic nematodes, replacing the need for multiple specialized treatments.
Data Source
AI summary
The present application relates to the treatment of nematode infections. For example, the application relates to the use of compounds of Formula (III) as defined herein for treatment of a nematode infection or a disease, disorder or condition arising from a nematode infection.